{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T01:51:50Z","timestamp":1776909110310,"version":"3.51.2"},"reference-count":16,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:p>Paraneoplastic pemphigus is a rare and severe autoimmune blistering disease characterized by a recalcitrant and severe mucositis, and polymorphic cutaneous lesions, associated with benign and malignant neoplasms. Paraneoplastic pemphigus is caused by production of autoantibodies against various epidermal proteins involved in cell adhesion. Bronchiolitis obliterans (BO) is one of the leading causes of mortality in these patients. Recent advances have associated the presence of anti-epiplakin antibodies with the development of BO in adult patients. Here we describe the first pediatric patient in whom the association of anti-epiplakin antibodies and BO have been reported so far.<\/jats:p>","DOI":"10.1542\/peds.2021-052132","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T08:10:26Z","timestamp":1643962226000},"source":"Crossref","is-referenced-by-count":3,"title":["Bronchiolitis Obliterans With Anti-Epiplakin Antibodies in a Boy With Paraneoplastic Pemphigus"],"prefix":"10.1542","volume":"149","author":[{"given":"Marian","family":"Rivas-Calderon","sequence":"first","affiliation":[{"name":"Dermatology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"Yamazaki-Nakashimada","sequence":"additional","affiliation":[{"name":"Immunology Department, National Institute of Pediatrics, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Orozco-Covarrubias","sequence":"additional","affiliation":[{"name":"Dermatology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Dur\u00e1n-McKinster","sequence":"additional","affiliation":[{"name":"Dermatology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deyanira","family":"Pacheco-Tovar","sequence":"additional","affiliation":[{"name":"Department of Immunology, Unidad Acad\u00e9mica de Ciencias Biol\u00f3gicas, Universidad Aut\u00f3noma de Zacatecas, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"\u00c1valos-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Immunology, Unidad Acad\u00e9mica de Ciencias Biol\u00f3gicas, Universidad Aut\u00f3noma de Zacatecas, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marimar","family":"S\u00e1ez-de-Ocariz","sequence":"additional","affiliation":[{"name":"Dermatology Department"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"issue":"5","key":"2022030200065806800_B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40272-019-00349-3","article-title":"Bullous diseases in children: a review of clinical features and treatment options","volume":"21","author":"Schultz","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"6","key":"2022030200065806800_B2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/bjd.14162","article-title":"Clinical and immunological findings in 104 cases of paraneoplastic pemphigus","volume":"173","author":"Ohzono","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"2022030200065806800_B3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/JID.2015.408","article-title":"Epiplakin is a paraneoplastic pemphigus autoantigen and related to bronchiolitis obliterans in japanese patients","volume":"136","author":"Tsuchisaka","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"25","key":"2022030200065806800_B4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1056\/NEJM199012203232503","article-title":"Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia","volume":"323","author":"Anhalt","year":"1990","journal-title":"N Engl J Med"},{"issue":"9","key":"2022030200065806800_B5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/cup.14004","article-title":"Paraneoplastic pemphigus: Revised diagnostic criteria based on literature analysis","volume":"48","author":"Svoboda","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"1","key":"2022030200065806800_B6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/1756-185X.13407","article-title":"Masked pemphigus among pediatric patients with Castleman\u2019s disease","volume":"22","author":"Han","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"2022030200065806800_B7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1590\/abd1806-4841.20199165","article-title":"Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview","volume":"94","author":"Maruta","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"10","key":"2022030200065806800_B8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ad.2017.04.024","article-title":"Paraneoplastic pemphigus. A life-threatening autoimmune blistering disease","volume":"108","author":"Tirado-S\u00e1nchez","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"2022030200065806800_B9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/2156-7514.177552","article-title":"Castleman\u2019s disease presenting as localized abdominal mass and paraneoplastic pemphigus","volume":"6","author":"Kumar","year":"2016","journal-title":"J Clin Imaging Sci"},{"issue":"1","key":"2022030200065806800_B10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.hoc.2017.09.005","article-title":"Diagnosis of Castleman disease","volume":"32","author":"Szalat","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"2022030200065806800_B11","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/RHU.0000000000000675","article-title":"Tocilizumab cannot prevent the development of bronchiolitis obliterans in patients with Castleman disease-associated paraneoplastic pemphigus","volume":"25","author":"Gu","year":"2019","journal-title":"J Clin Rheumatol"},{"issue":"18","key":"2022030200065806800_B12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199905063401805","article-title":"The mechanism of respiratory failure in paraneoplastic pemphigus","volume":"340","author":"Nousari","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"2022030200065806800_B13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJM200307243490421","article-title":"CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus, and solitary Castleman\u2019s disease","volume":"349","author":"Hoffman","year":"2003","journal-title":"N Engl J Med"},{"key":"2022030200065806800_B14","first-page":"129","article-title":"Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus","volume":"25","author":"Raza","year":"2018","journal-title":"Respir Med Case Rep"},{"issue":"5","key":"2022030200065806800_B15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.09-2084","article-title":"Treatment of unicentric Castleman disease with neoadjuvant rituximab","volume":"138","author":"Bandera","year":"2010","journal-title":"Chest"},{"issue":"10","key":"2022030200065806800_B16","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1111\/1346-8138.15496","article-title":"Successful treatment with i.v. immunoglobulin and rituximab for bronchiolitis obliterans associated with paraneoplastic pemphigus","volume":"47","author":"Kaibuchi-Ando","year":"2020","journal-title":"J Dermatol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-052132\/1266702\/peds_2021052132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-052132\/1266702\/peds_2021052132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:07:14Z","timestamp":1646179634000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/149\/3\/e2021052132\/184740\/Bronchiolitis-Obliterans-With-Anti-Epiplakin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,4]]},"published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2021-052132","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"article-number":"e2021052132"}}